---
title: 'Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based
  Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1
  &lt;1%: a Pooled Analysis'
date: '2024-10-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39369790/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241007200555&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: Nivolumab plus ipilimumab with or without chemotherapy provides
  a long-term, durable clinical benefit in patients with metastatic NSCLC and tumor
  PD-L1 <1%, supporting the use of this strategy as a first-line treatment option
  in this population with high unmet ...'
disable_comments: true
---
CONCLUSION: Nivolumab plus ipilimumab with or without chemotherapy provides a long-term, durable clinical benefit in patients with metastatic NSCLC and tumor PD-L1 <1%, supporting the use of this strategy as a first-line treatment option in this population with high unmet ...